Overview

Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL

Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
To determine the response to the combination of azacitidine + lenalidomide in patients with relapsed/refractory CLL and SLL Hypothesize - lenalidomide's activity in combination with azacitidine may further enhance its activity and the durability of treatment response.
Phase:
Phase 2
Details
Lead Sponsor:
Hackensack Meridian Health
Hackensack University Medical Center
Collaborator:
Celgene Corporation
Treatments:
Azacitidine
Lenalidomide
Thalidomide